Last reviewed · How we verify

NCT03126305: OC-GoPhaseI

Initial Development and Dissemination of OC-Go

Completed Last updated 18 November 2020
What this trial tests

trial testing OC-Go in Obsessive-Compulsive Disorder in 8 participants. Completed in 30 April 2018.

Timeline
1 May 2017
Primary endpoint
30 April 2018
30 April 2018

Quick facts

Lead sponsorUniversity of California, Los Angeles
StatusCompleted
Study typeOBSERVATIONAL
Enrollment8
Start date1 May 2017
Primary completion30 April 2018
Estimated completion30 April 2018
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

University of California, Los Angeles

Who can join

Adults 9 to 17, any sex, with Obsessive-Compulsive Disorder. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The clinical component of Phase I application development examines the clinical utility, feasibility, and functionality of the OC-Go application via an 8-month pilot trial consisting of 50 standard CBT sessions augmented with OC-Go in OCD-diagnosed children who are receiving treatment through the pediatric OCD treatment programs in the UCLA Division of Child and Adolescent Psychiatry

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of OC-Go

Trials testing the same drug.

Other recruiting trials for Obsessive-Compulsive Disorder

Currently open trials in the same condition.

Other University of California, Los Angeles trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03126305.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing